Restore Medical

High-Level Overview

Restore Medical is an Israeli clinical-stage medtech company founded in 2015 that develops innovative transcatheter devices for treating congestive heart failure (CHF), particularly heart failure with reduced ejection fraction (HFrEF).[1][3][5] Its flagship product, ContraBand, is a reversible, catheter-delivered pulmonary artery banding (PAB) system that leverages the right ventricle to support the left ventricle, improving ejection fraction, restoring ventricular geometry, and enhancing patient outcomes for those with persistent symptoms despite guideline-directed medical therapy (GDMT).[1][2][5] The company serves healthcare providers and HFrEF patients underserved by current treatments, addressing a massive unmet need in cardiology where heart failure drives high hospitalization and mortality rates; recent momentum includes FDA Breakthrough Device Designation in 2024 and a $23M Series B round in July 2025 to fund European and U.S. trials.[1][2][3]

Origin Story

Restore Medical emerged from Peregrine Ventures' Incentive Incubator in Or Yehuda, Israel, co-founded by CTO Stephen Bellomo, Medical Director Dr. Elchanan Bruckheimer, and Aaron Feldman, with CEO Gilad Marom—a medical device industry veteran—leading operations.[3][4] The idea stemmed from the need for minimally invasive solutions in interventional cardiology for CHF patients lacking effective therapies beyond drugs, focusing on hemodynamic balance via transcatheter pulmonary artery banding.[1][5] Early traction included a first-in-human study in 2024 showing improved symptoms and ejection fraction in 15 GDMT patients, followed by FDA Breakthrough Designation and promising European feasibility data on safety, efficacy, reverse remodeling, and functional capacity.[1][3][4]

Core Differentiators

• Revolutionary Product Design: ContraBand is the first fully reversible transcatheter PAB system, avoiding open-heart surgery while leveraging the right ventricle for left ventricular support—unique in restoring geometry, improving ejection fraction, and enabling simple, time-effective implantation.[2][5]
• Clinical Validation: Ongoing trials demonstrate long-term safety, hemodynamic improvements, reduced remodeling, and better patient capacity; FDA Breakthrough Designation accelerates U.S. approval for high-need HFrEF cases.[1][3]
• Minimally Invasive Edge: Addresses gaps in CHF care with no metal implants, reversibility, and focus on undertreated patients, potentially cutting hospitalizations and costs.[1][4][5]

Role in the Broader Tech Landscape

Restore Medical rides the transcatheter revolution in cardiology, mirroring trends in structural heart devices like TAVR for aortic stenosis, amid rising CHF prevalence driven by aging populations and post-COVID cardiac strain.[1][2][4] Timing is ideal post-2024 FDA nod and 2025 funding, aligning with regulatory fast-tracks for breakthrough tech amid market forces favoring outpatient, reversible interventions over pharmaceuticals with limited efficacy.[3] It influences the ecosystem by pioneering right-heart utilization for left failure, potentially expanding medtech options in a $50B+ CHF market and inspiring hybrid hemodynamic therapies.[1][5]

Quick Take & Future Outlook

With $23M fueling U.S. pivotal trials and European completion, Restore Medical is poised for FDA approval by 2027-2028, targeting commercial launch amid surging demand for CHF innovations.[2][3] Trends like AI-enhanced imaging and value-based care will amplify its impact, evolving it from niche player to category leader in reversible heart failure tech—transforming lives as Marom envisions, much like its origins in incubator ingenuity promised.[1][3]